Letter: New vasodilator drugs for hypertension

Bolli, P; Simpson, F O
March 1974
British Medical Journal;3/30/1974, Vol. 1 Issue 5908, p637
Academic Journal
No abstract available.


Related Articles

  • RN'S DRUG DATA BANK.  // RN;May80, Vol. 43 Issue 5, p152 

    Provides information minoxidil, a direct-acting peripheral vasodilator for severe hypertension. Indications of the drug; Why the drug is contraindicated in pheochromocytoma.

  • Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Fukumoto, Y.; Matoba, T.; Ito, A.; Tanaka, H.; Kishi, T.; Hayashidani, S.; Abe, K.; Takeshita, A.; Shimokawa, H. // Heart;Mar2005, Vol. 91 Issue 3, p391 

    Presents a letter to the editor related to acute vasodilator effects of fusadil in patients with severe pulmonary hypertension.

  • Vasodilator Therapy for Primary Pulmonary Hypertension. Packer, Milton // Annals of Internal Medicine;Aug85, Vol. 103 Issue 2, p258 

    Evaluates the efficacy of vasodilator therapy for primary pulmonary hypertension. Information on how vasolidator drugs are administered; Medical cases; Discussion on the results of the treatment.

  • Beta blocker/vasodilator.  // Geriatrics;Mar96, Vol. 51 Issue 3, p19 

    Reports on the Food and Drug Administration approval of Carvedilol, a beta blocker with vasodilating activity, for the use in the management of essential hypertension. Recommended initial dosage; Contraindications; Adverse reactions.

  • VASODILATOR DRUGS AND RESISTANT HYPERTENSION. Bannan, Liam T.; Beevers, D.G.; Wright, Noel // British Medical Journal;10/18/1980, Vol. 281 Issue 6247, p1053 

    Presents vasodilator drugs for hypertensives. Action of Hydralazine on arterioles; Role of Prazasin in blocking peripheral postsynaptic alpha receptors; effects of Reserpine on depleting postsympathetic neurons of noradrenaline.

  • Vasoproliferation and Antiproliferative Treatment Options in Pulmonary Arterial Hypertension. Blaukovitsch, Markus; Zabel, Peter; Hauber, Hans-Peter // Recent Patents on Cardiovascular Drug Discovery;Jun2009, Vol. 4 Issue 2, p142 

    New treatment options have improved the prognosis of patients with pulmonary arterial hypertension. However, drugs such as prostanoids, PDE5 inhibitors and endothelin receptor antagonists mainly act as vasodilating agents. Recently, it has become clear that pulmonary arterial hypertension is an...

  • Recognition and Management of Pulmonary Hypertension. Wanstall, J.C.; Jeffery, T.K. // Drugs;Dec1998, Vol. 56 Issue 6, p989 

    Pulmonary hypertension (mean pulmonary arterial pressure >20mm Hg at rest or >30mm Hg during exercise) occurs (i) as primary pulmonary hypertension (no known underlying cause), (ii) as persistent pulmonary hypertension of the newborn or (iii) secondary to a variety of lung and cardiovascular...

  • Positive antinuclear factor tests with prazosin. Marshall, A.J.; McGraw, M.E.; Barritt, D.W. // British Medical Journal;1/20/1979, Vol. 1 Issue 6157, p165 

    Presents the antinuclear factor (ANF) tests with prazosin. Discussions on the important symptomatic side effects; Evaluations on the testing for ANF for hypertensive patients; Association of LE cells with peripheral vasodilator drugs.

  • Antihypertensive agents your patient is likely to take.  // RN;Jan94, Vol. 57 Issue 1, p29 

    Presents information on drugs for hypertension patients. Diuretics; Adrenergic inhibitors; ACE inhibitors; Calcium antagonists; Centrally acting alpha2-agonists; Peripheral acting adrenergic antagonists; Direct vasodilators.

  • The Maze of Vasodilator Response Criteria. Douwes, J. Menno; Berger, Rolf M. F. // Pediatric Cardiology;Feb2011, Vol. 32 Issue 2, p245 

    A letter to the editor is presented in response to the article "Vasodilator testing with nitric oxide and/or oxygen in pediatric pulmonary hypertension," by RJ Barst and colleagues in the 2010 issue.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics